Aprinoia Therapeutics (Aprinoia Therapeutics) Net Margin % : -79.53% (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Aprinoia Therapeutics's Net Income for the six months ended in Jun. 2023 was $-7.19 Mil. Aprinoia Therapeutics's Revenue for the six months ended in Jun. 2023 was $9.03 Mil. Therefore, Aprinoia Therapeutics's net margin for the quarter that ended in Jun. 2023 was -79.53%.

The historical rank and industry rank for Aprinoia Therapeutics's Net Margin % or its related term are showing as below:

APRI's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -162.84
* Ranked among companies with meaningful Net Margin % only.

Aprinoia Therapeutics Net Margin % Historical Data

The historical data trend for Aprinoia Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Net Margin % Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Net Margin %

-4,229.27

-7,165.23

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Net Margin %	-	-4,635.93	-14,702.02	-79.53

Competitive Comparison of Aprinoia Therapeutics's Net Margin %

For the Biotechnology subindustry, Aprinoia Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Net Margin % falls into.

Aprinoia Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Aprinoia Therapeutics's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-28.231	/	0.394
	=	-7,165.23 %

Aprinoia Therapeutics's Net Margin for the quarter that ended in Jun. 2023 is calculated as

Net Margin	=	Net Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-7.185	/	9.034
	=	-79.53 %

Aprinoia Therapeutics (NAS:APRI) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Aprinoia Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines